Related Experiment Videos
Downregulation of hepatic acyl-CoA:diglycerol acyltransferase in chronic renal failure
1Division of Nephrology and Hypertension, University of California, Irvine, Orange, CA 92868, USA. ndvaziri@uci.edu
Abstract:
Chronic renal failure (CRF) is associated with hypertriglyceridemia and elevated plasma VLDL and IDL concentrations. These events can be due to either increased production or depressed catabolism of triglyceride-rich lipoproteins. Several studies have documented downregulation of lipoprotein lipase, hepatic triglyceride lipase, and the VLDL receptor, leading to depressed clearance and elevated plasma concentration of triglyceride-rich lipoproteins and their remnants in CRF. However, the effect of CRF on the triglyceride biosynthetic pathway has not been explored. Diglycerol acyltransferase (DGAT) is a microsomal enzyme that joins acyl-CoA to 1,2 diacylglycerol and, as such, constitutes the final step in triglyceride biosynthesis. Two distinct forms of DGAT (DGAT-1 and -2) have thus far been identified. The present study was undertaken to examine the effect of CRF on DGAT gene expression and activity in the liver, which is the source of endogenous triglycerides in the circulation. Male Sprague-Dawley rats were studied 8 wk after 5/6 nephrectomy (CRF) or sham operation. DGAT-1 and DGAT-2 mRNA abundance and DGAT activity were quantified. The CRF group showed reduced creatinine clearance, elevated plasma triglycerides, and VLDL concentrations. This was accompanied by significant reductions in hepatic DGAT-2 mRNA abundance (P < 0.01) and total DGAT activity (P < 0.1), pointing to diminished hepatic triglyceride production capacity in CRF animals. In conclusion, CRF results in significant downregulation of hepatic DGAT gene expression and activity. Given the critical role of DGAT in triglyceride biosynthesis, the present study points to diminished, not increased, hepatic triglyceride synthetic capacity in CRF rats.
Insights
Chronic renal failure (CRF) diminishes hepatic triglyceride synthesis by downregulating diglycerol acyltransferase (DGAT) gene expression and activity. This finding suggests reduced liver triglyceride production in CRF, contrary to previous assumptions.
Area of Science:
- Nephrology
- Biochemistry
- Molecular Biology
Background:
- Chronic renal failure (CRF) is linked to hypertriglyceridemia and elevated VLDL/IDL, potentially due to altered lipoprotein metabolism.
- Previous research focused on reduced clearance of triglyceride-rich lipoproteins in CRF.
- The impact of CRF on hepatic triglyceride synthesis remained unexplored.
Purpose of the Study:
- To investigate the effect of CRF on diglycerol acyltransferase (DGAT) gene expression and activity in the liver.
- To determine if CRF alters the hepatic triglyceride biosynthesis pathway.
Main Methods:
- Male Sprague-Dawley rats underwent 5/6 nephrectomy (CRF) or sham operation.
- Liver samples were analyzed for DGAT-1 and DGAT-2 mRNA abundance.
- Hepatic DGAT activity was quantified.
Main Results:
- CRF rats exhibited reduced creatinine clearance and elevated plasma triglycerides and VLDL.
- Significant reductions in hepatic DGAT-2 mRNA abundance (P < 0.01) were observed in CRF rats.
- Total hepatic DGAT activity showed a significant decrease (P < 0.1) in CRF animals.
Conclusions:
- CRF leads to significant downregulation of hepatic DGAT gene expression and activity.
- This indicates a diminished hepatic triglyceride production capacity in CRF.
- The study suggests reduced, not increased, hepatic triglyceride synthesis in CRF rats.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Diabetic Nephropathy